1. The price of innovation: new estimates of drug development costs;DiMasi;J Health Econ,2003
2. Slow start to phase 0 as researchers debate value;Twombly;J Natl Cancer Inst,2006
3. Can the pharmaceutical industry reduce attrition rates?;Kola;Nat Rev Drug Discov,2004
4. Goodall S. Rising to the productivity challenge: a strategic framework for Biopharma. The Boston Consulting Group Report 2004. .
5. Risk in new drug development: approval success rate for investigational drugs;DiMasi;Clin Pharmacol Ther,2001